Adoptive Cell rapy - Tumor-Infiltrating Lymphocytes, T-Cell Receptors, and Chimeric Antigen Receptors

Seminars in Oncology

Volumn 42, Issue 4, 2015, Pages 626-639

  Feldman, Steven A ^a   Assadipour, Yasmine ^a   Kriley, Isaac ^a   Goff, Stephanie L ^a   Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; T LYMPHOCYTE RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR; TUMOR ANTIGEN;

ADOPTIVE CELL THERAPY; ARTICLE; CELL THERAPY; GENE THERAPY; HEMATOLOGIC MALIGNANCY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; T LYMPHOCYTE; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; ADOPTIVE IMMUNOTHERAPY; ANIMAL; BIOLOGICAL THERAPY; IMMUNOLOGY; NEOPLASMS; PROCEDURES;

ANIMALS; ANTIGENS, NEOPLASM; CELL- AND TISSUE-BASED THERAPY; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASMS; RECEPTORS, ANTIGEN; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 84940379637     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2015.05.005     Document Type: Review

References (99)

1. S.A. Rosenberg, E.A. Grimm, M. McGrogan, and et al. Biological activity of recombinant human interleukin-2 produced in escherichia coli Science 223 1984 1412 1415
2. S.A. Rosenberg, M.T. Lotze, L.M. Muul, and et al. Observations on systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer N Engl J Med 313 1985 1485 1492
3. S.A. Rosenberg, M.T. Lotze, J.C. Yang, and et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for treatment of patients with advanced cancer J Natl Cancer Inst 85 1993 622 632
4. S.A. Rosenberg, P. Speiss, and R. Lafreniere A new approach to adoptive immunorapy of cancer with tumor-infiltrating lymphocytes Science 233 1986 1318 1321
5. S.A. Rosenberg, B.S. Packard, P.M. Aebersold, and et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in immunorapy of patients with metastatic melanoma N Engl J Med 319 1988 1676 1680
6. M.E. Dudley, J.R. Wunderlich, J.C. Yang, and et al. Adoptive cell transfer rapy following non-myeloablative but lymphodepleting chemorapy for treatment of patients with refractory metastatic melanoma J Clin Oncol 23 2005 2346 2357
7. M.E. Dudley, J.C. Yang, R. Sherry, and et al. Adoptive cell rapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens J Clin Oncol 26 2008 5233 5239
8. E.A. Eisenhauer, P. rasse, J. Bogaerts, and et al. New response evaluation criteria in solid tumours: Revised recist guideline (version 1.1) Eur J Cancer 45 2009 228 247
9. S.L. Goff, F.O. Smith, J.A. Klapper, and et al. Tumor infiltrating lymphocyte rapy for metastatic melanoma: Analysis of tumors resected for til J Immunor 33 2010 840 847
10. S. Pilon-Thomas, L. Kuhn, S. Ellwanger, and et al. Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma J Immunor 35 2012 615 620
11. L. Gattinoni, S.E. Finkelstein, C.A. Klebanoff, and et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances efficacy of adoptively transferred tumor-specific CD8+T cells J Expt Med 202 2005 907 912
12. C. Wrzesinski, C.M. Paulos, A. Kaiser, and et al. Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells J Immunor 33 2010 1 7
13. S.A. Rosenberg, J.C. Yang, R.M. Sherry, and et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunorapy Clin Cancer Res 17 2011 4550 4557
14. J. Zhou, X. Shen, J. Huang, R.J. Hodes, S.A. Rosenberg, and P.F. Robbins Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer rapy J Immunol 175 2005 7046 7052
15. O. Itzhaki, E. Hovav, Y. Ziporen, and et al. Establishment and large-scale expansion of minimally cultured "young" tumor infiltrating lymphocytes for adoptive transfer rapy J Immunor 34 2011 212 220
16. L.G. Radvanyi, C. Bernatchez, M. Zhang, and et al. Specific lymphocyte subsets predict response to adoptive cell rapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients Clin Cancer Res 18 2012 6758 6770
17. M.E. Dudley, C.A. Gross, R.P.T. Somerville, and et al. Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell rapy for patients with melanoma J Clin Oncol 31 2013 2152 2159
18. E. Ellebaek, T. Iversen, N. Junker, and et al. Adoptive cell rapy with autologous tumor infiltrating lymphocytes and low-dose interleukin-2 in metastatic melanoma patients J Transl Med 10 2012 169
19. M.J. Besser, R. Shapira-Frommer, O. Itzhaki, and et al. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: Intent-to-treat analysis and efficacy after failure to prior immunorapies Clin Cancer Res 19 2013 4792 4800
20. J.R. Webb, K. Milne, P. Watson, R.J. deLeeuw, and B.H. Nelson Tumor-infiltrating lymphocytes expressing tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer Clin Cancer Res 20 2014 434 444
21. S. Aaltomaa, P. Lipponen, M. Eskelinen, and et al. Lymphocyte infiltrates as a prognostic variable in female breast cancer Eur J Cancer 28 1992 859 864
22. Ras L Hilders CGJM, J.D.H. van Eendenburg, Y. Nooyen, and G.J. Fleuren Isolation and characterization of tumor-infiltrating lymphocytes from cervical carcinoma Intl J Cancer 57 1994 805 813
23. J.R. Yannelli, C. Hyatt, S. McConnell, and et al. Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience Intl J Cancer 65 1996 413 421
24. S. Turcotte, A. Gros, K. Hogan, and et al. Phenotype and function of t cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer rapy J Immunol 191 2013 2217 2225
25. S.A. Rosenberg, J.C. Yang, D.E. White, and S.M. Steinberg Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of antigens mediating response Ann Surg 228 1998 307 319
26. A.B. Bakker, M.W. Schreurs, A.J. de Boer, and et al. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes J Exp Med 179 1994 1005 1009
27. Y. Kawakami, S. Eliyahu, C.H. Delgado, and et al. Cloning of gene coding for a shared human melanoma antigen recognized by autologous t cells infiltrating into tumor Proc Natl Acad Sci U S A 91 1994 3515 3519
28. Y. Kawakami, S. Eliyahu, C.H. Delgado, and et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection Proc Natl Acad Sci U S A 91 1994 6458 6462
29. P.F. Robbins, M. El-Gamil, Y. Kawakami, and S.A. Rosenberg Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunorapy Cancer Res 54 1994 3124 3126
30. S. Rosenberg Development of cancer immunorapies based on identification of genes encoding cancer regression antigens J Natl Cancer Inst 88 1996 1635 1644
31. R.F. Wang, P.F. Robbins, Y. Kawakami, X.Q. Kang, and S.A. Rosenberg Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes J Exp Med 181 1995 799 804
32. E. Tran, S. Turcotte, A. Gros, and et al. Cancer immunorapy based on mutation-specific CD4+T cells in a patient with epilial cancer Science 344 2014 641 645
33. G. Gross, T. Waks, and Z. Eshhar Expression of immunoglobulin-t-cell receptor chimeric molecules as functional receptors with antibody-type specificity Proc Natl Acad Sci U S A 86 1989 10024 10028
34. R.A. Morgan, M.E. Dudley, J.R. Wunderlich, and et al. Cancer regression in patients after transfer of genetically engineered lymphocytes Science 314 2006 126 129
35. L.A. Johnson, B. Heemskerk, D.J. Powell Jr., and et al. Gene transfer of tumor-reactive tcr confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes J Immunol 177 2006 6548 6559
36. L.A. Johnson, R.A. Morgan, M.E. Dudley, and et al. Gene rapy with human and mouse t-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen Blood 114 2009 535 546
37. L.A. Johnson, R.A. Morgan, M.E. Dudley, and et al. Gene rapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen Blood 114 2009 535 546
38. L. Duval, H. Schmidt, K. Kaltoft, and et al. Adoptive transfer of allogeneic cytotoxic t lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: A phase I trial in metastatic melanoma Clin Cancer Res 12 2006 1229 1236
39. M.R. Parkhurst, J.C. Yang, R.C. Langan, and et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis Mol r 19 2011 620 626
40. M. Bilusic, C. Heery, P. Arlen, and et al. Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma Cancer Immunol Immunor 63 2014 225 234
41. J.L. Gulley, P.M. Arlen, K.-Y. Tsang, and et al. Pilot study of vaccination with recombinant CEA-MUC-1-tricom poxviral-based vaccines in patients with metastatic carcinoma Clin Cancer Res 14 2008 3060 3069
42. J.L. Marshall, J.L. Gulley, P.M. Arlen, and et al. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-tricom alone and sequentially with vaccinia-CEA(6D)-tricom, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas J Clin Oncol 23 2005 720 731
43. R.M. Sharkey, M. Juweid, J. Shevitz, and et al. Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies Cancer Res 55 1995 5935s 5945s
44. P.F. Robbins, Y.F. Li, M. El-Gamil, and et al. Single and dual amino acid substitutions in TCR CDRS can enhance antigen-specific T cell functions J Immunol 180 2008 6116 6131
45. D. Sommermeyer, and W. Uckert Minimal amino acid exchange in human TCR constant regions fosters improved function of TCR gene-modified T cells J Immunol 184 2010 6223 6231
46. A.J.G. Simpson, O.L. Caballero, A. Jungbluth, Y.-T. Chen, and L.J. Old Cancer/testis antigens, gametogenesis and cancer Nat Rev Cancer 5 2005 615 625
47. O. Hofmann, O.L. Caballero, B.J. Stevenson, and et al. Genome-wide analysis of cancer/testis gene expression Proc Natl Acad Sci U S A 105 2008 20422 20427
48. Y.-T. Chen, M.J. Scanlan, U. Sahin, and et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening Proc Natl Acad Sci U S A 94 1997 1914 1918
49. A.A. Jungbluth, C.R. Antonescu, K.J. Busam, and et al. Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7 Intl J Cancer 94 2001 252 256
50. P.F. Robbins, R.A. Morgan, S.A. Feldman, and et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1 J Clin Oncol 29 2011 917 924
51. N. Chinnasamy, J.A. Wargo, Z. Yu, and et al. A TCR targeting HLA-A∗0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of MAGE-A antigen superfamily in several types of cancer J Immunol 186 2011 685 696
52. R.A. Morgan, N. Chinnasamy, D. Abate-Daga, and et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene rapy J Immunor 36 2013 133 151
53. B.J. Cameron, A.B. Gerry, J. Dukes, and et al. Identification of a titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells Sci Transl Med 5 2013 197ra03
54. G.P. Linette, E.A. Stadtmauer, M.V. Maus, and et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma Blood 122 2013 863 871
55. B.C. Leibovich, Y. Sheinin, C.M. Lohse, and et al. Carbonic anhydrase ix is not an independent predictor of outcome for patients with clear cell renal cell carcinoma J Clin Oncol 25 2007 4757 4764
56. A.H. Brouwers, P.F.A. Mulders, and W.J.G. Oyen Carbonic anhydrase IX expression in clear cell renal cell carcinoma and normal tissues: Experiences from (radio) immunorapy J Clin Oncol 26 2008 3808 3809
57. S. Ivanov, S.-Y. Liao, A. Ivanova, and et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer Am J Pathol 158 2001 905 919
58. C.H. Lamers, S. Sleijfer, A.G. Vulto, W.H. Kruit, M. Kliffen, and R. Debets Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: First clinical experience J Clin Oncol 24 2006 e20 e22
59. C.H.J. Lamers, S. Sleijfer, S. van Steenbergen, and et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: Clinical evaluation and management of on-target toxicity Mol r 21 2013 904 912
60. J.R. Park, D.L. DiGiusto, M. Slovak, and et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma Mol r 15 2007 825 833
61. M.A. Pule, B. Savoldo, G.D. Myers, and et al. Virus-specific t cells engineered to coexpress tumor-specific receptors: Persistence and antitumor activity in individuals with neuroblastoma Nat Med 14 2008 1264 1270
62. C.U. Louis, B. Savoldo, G. Dotti, and et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma Blood 118 2011 6050 6056
63. Y. Zhao, Q.J. Wang, S. Yang, and et al. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity J Immunol 183 2009 5563 5574
64. R.A. Morgan, J.C. Yang, M. Kitano, M.E. Dudley, C.M. Laurencot, and S.A. Rosenberg Case report of a serious adverse event following administration of T cells transduced with a chimeric antigen receptor recognizing ErbB2 Mol r 18 2010 843 851
65. P. Argani, C. Iacobuzio-Donahue, B. Ryu, and et al. Mesolin is overexpressed in vast majority of ductal adenocarcinomas of pancreas Clin Cancer Res 7 2001 3862 3868
66. K. Chang, and I. Pastan Molecular cloning of mesolin, a differentiation antigen present on mesolium, mesoliomas, and ovarian cancers Proc Natl Acad Sci U S A 93 1996 136 140
67. G.L. Beatty, A.R. Haas, M.V. Maus, and et al. Mesolin-specific chimeric antigen receptor MRNA-engineered T cells induce antitumor activity in solid malignancies Cancer Immunol Res 2 2014 112 120
68. R. Morgan, L. Johnson, J. Davis, and et al. Recognition of glioma stem cells by genetically modified T cells targeting EGFRVIII and development of adoptive cell rapy for glioma Hum Gene r 23 2012 1043 1053
69. D. Chinnasamy, Z. Yu, M.R. oret, and et al. Gene rapy using genetically modified lymphocytes targeting VEGFR-2 inhibits growth of vascularized syngenic tumors in mice J Clin Invest 120 2010 3953 3968
70. N. Mounier, N. Heutte, C. Thieblemont, and et al. Ten-year relative survival and causes of death in elderly patients treated with R-CHOP or CHOP in GELA LNH-985 trial Clin Lymphoma Myeloma Leuk 12 2012 151 154
71. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemorapy (PRIMA): A phase 3, randomised controlled trial. Lancet. 2011;377:42-51.
72. F. Morschhauser, N. Mounier, C. Sebban, and et al. Efficacy and safety of combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-hodgkin lymphoma with high tumor burden Cancer 116 2010 4299 4308
73. P. Feugier, A. Van Hoof, C. Sebban, and et al. Long-term results of R-CHOP study in treatment of elderly patients with diffuse large B-cell lymphoma: A study by Groupe d'Etude des Lymphomes de l'Adulte J Clin Oncol 23 2005 4117 4126
74. + indolent NHL: Correlation between clinical responses and AUC pharmacokinetics Clin Immunol 154 2014 37 46
75. B.G. Till, M.C. Jensen, J. Wang, and et al. Adoptive immunorapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells Blood 112 2008 2261 2271
76. B.G. Till, M.C. Jensen, J. Wang, and et al. CD20-specific adoptive immunorapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: Pilot clinical trial results Blood 119 2012 3940 3950
77. R.H. Scheuermann, and E. Racila CD19 antigen in leukemia and lymphoma diagnosis and immunorapy Leuk Lymphoma 18 1995 385 397
78. F. Uckun, W. Jaszcz, J. Ambrus, and et al. Detailed studies on expression and function of cd19 surface determinant by using B43 monoclonal antibody and clinical potential of anti-CD19 immunotoxins Blood 71 1988 13 29
79. L.M. Nadler, K.C. Anderson, G. Marti, and et al. B4, a human b lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes J Immunol 131 1983 244 250
80. J.N. Kochenderfer, W.H. Wilson, J.E. Janik, and et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19 Blood 116 2010 4099 4102
81. J.N. Kochenderfer, M.E. Dudley, S.A. Feldman, and et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells Blood 119 2012 2709 2720
82. Kochenderfer JN, Dudley ME, Kassim SH, et al. Chemorapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2014;33(6):540-9.
83. M. Kalos, B.L. Levine, D.L. Porter, and et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia Sci Transl Med 3 2011 95ra73
84. D.L. Porter, B.L. Levine, M. Kalos, and A. Bagg June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia N Engl J Med 365 2011 725 733
85. S.A. Grupp, M. Kalos, D. Barrett, and et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia N Engl J Med 368 2013 1509 1518
86. R.J. Brentjens, M.L. Davila, I. Riviere, and et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemorapy-refractory acute lymphoblastic leukemia Sci Transl Med 5 2013 177 185
87. R.J. Brentjens, I. Rivière, J.H. Park, and et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemorapy refractory B-cell leukemias Blood 118 2011 4817 4828
88. M.L. Davila, I. Riviere, X. Wang, and et al. Efficacy and toxicity management of 19-28Z CAR T cell rapy in B cell acute lymphoblastic leukemia Sci Transl Med 6 2014 224 233
89. D.W. Lee, J.N. Kochenderfer, M. Stetler-Stevenson, and et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial Lancet 385 9967 2014 517 528
90. S.L. Maude, N. Frey, P.A. Shaw, and et al. Chimeric antigen receptor T cells for sustained remissions in leukemia N Engl J Med 371 2014 1507 1517
91. C.R.Y. Cruz, K.P. Micklethwaite, B. Savoldo, and et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: A phase 1 study Blood 122 2013 2965 2973
92. W. Haso, D.W. Lee, N.N. Shah, and et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia Blood 121 2013 1165 1174
93. S.E. James, P.D. Greenberg, M.C. Jensen, and et al. Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from cell membrane J Immunol 180 2008 7028 7038
94. G.M.P. Giordano Attianese, V. Marin, and et al. In vitro and in vivo model of a novel immunorapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor Gene r 117 2011 4736 4745
95. M. Hudecek, T.M. Schmitt, S. Baskar, and et al. B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor Blood 116 2010 4532 4541
96. J. Vera, B. Savoldo, S. Vigouroux, and et al. T lymphocytes redirected against κ light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells Neoplasia 108 2006 3890 3897
97. R.O. Carpenter, M.O. Evbuomwan, S. Pittaluga, and et al. B-cell maturation antigen is a promising target for adoptive T-cell rapy of multiple myeloma Clin Cancer Res 19 2013 2048 2060
98. A. Gros, P.F. Robbins, X. Yao, and et al. Pd-1 identifies patient-specific CD8+tumor-reactive repertoire infiltrating human tumors J Clin Invest 124 2014 2246 2259
99. S.P. Kerkar, A.J. Leonardi, N. van Panhuys, and et al. Collapse of tumor stroma is triggered by IL-12 induction of fas Mol r 21 2013 1369 1377